Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV Trial
Cherney D, Frederich R, Pratley R, Cosentino F, Dagogo-Jack S, Pong A, Gantz I, Cater N, Mancuso J, Masiukiewicz U, Cannon C. Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV Trial. Kidney Diseases 2025, 11: 63-74. PMID: 40028005, PMCID: PMC11870670, DOI: 10.1159/000543162.Peer-Reviewed Original ResearchRenin-angiotensin-aldosterone system inhibitorsMineralocorticoid receptor antagonistsRenin-angiotensin-aldosterone systemUse of diureticsLoop diureticsVERTIS CVBaseline useCardiorenal outcomesReceptor antagonistTreated with RAAS inhibitorsErtugliflozin 5 mgKidney composite outcomeCox proportional hazards modelsAtherosclerotic CV diseaseTreatment effect modificationModification of treatment effectsProportional hazards modelType 2 diabetesErtugliflozin treatmentPlacebo-controlledRenal outcomesEvent of hospitalizationKidney outcomesSystem inhibitorsRAAS inhibitors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply